← All events
Workshop Pharmacokinetics

AAPS PBPK Modelling
Workshop 2027

Mar 10–12, 2027 · Boston, MA · Hands-on modelling
Visit AAPS.org ↗

About the AAPS PBPK Workshop

The AAPS PBPK Modelling Workshop ↗ is a focused 3-day hands-on training event designed for pharmaceutical scientists, pharmacokineticists, and regulatory scientists who need working knowledge of physiologically based pharmacokinetic modelling. Unlike large symposia, the workshop format limits attendance to ~200 participants, enabling direct interaction with expert instructors and platform vendors.

The 2027 Boston workshop covers PBPK model building, parameter estimation, validation strategies, and regulatory submission best practices across Simcyp ↗, GastroPlus ↗, and PK-Sim ↗ platforms. Sessions are aligned with the FDA PBPK Guidance (2018) ↗ and EMA PBPK Reporting Guideline ↗.

Regulatory PBPK Applications Covered

Application Key considerations Regulatory guidance
DDI prediction Inhibition/induction of CYP3A4, CYP2D6, transporters FDA DDI Guidance, ICH M12
Paediatric dose selection Enzyme ontogeny, GFR maturation, body composition scaling EMA PIP, FDA PREA
Renal impairment dosing GFR-dependent clearance reduction, transporter changes FDA Renal Guidance 2020
Hepatic impairment dosing Child-Pugh A/B/C; reduced CYP expression, portal shunting FDA Hepatic Guidance 2003
Food effect prediction Gastric pH, bile salts, gastric emptying, splanchnic blood flow FDA Food Effect Guidance
Formulation bridging IR to MR conversion, BCS class, dissolution-linked absorption FDA BCS Guidance

Workshop Sessions

PBPK Fundamentals

Model structure, compartmental physiology, parameter sourcing, mass balance equations, and model implementation in Simcyp/GastroPlus/PK-Sim.

DDI Prediction

CYP inhibition (reversible, time-dependent), induction (PXR/CAR), transporter DDI, and PBPK-based DDI study waiver strategies for FDA/EMA.

Paediatric Extrapolation

Enzyme ontogeny, GFR maturation, allometric scaling, neonatal PK, and PREA/PIP regulatory pathway integration.

Special Populations

Renal and hepatic impairment PBPK, pregnancy PK modelling, obese patient PK, and geriatric physiology.

Regulatory Submissions

FDA and EMA PBPK submission format, model verification/validation reports, sensitivity analyses, and case studies from approved NDAs.

Hands-On Platform Sessions

Supervised modelling exercises in Simcyp, GastroPlus, and PK-Sim with expert instructors; Q&A with platform developers.

Related DrugTheGuide resources

Frequently asked questions

What is physiologically based pharmacokinetic (PBPK) modelling?
PBPK modelling uses physiological parameters (organ volumes, blood flows, CYP enzyme expression, plasma protein concentrations) rather than empirical compartments to simulate ADME processes. Unlike classical one- or two-compartment models, PBPK models can extrapolate to unstudied populations — paediatrics, renal impairment, hepatic impairment — by adjusting tissue physiology. See the FDA PBPK guidance ↗ for regulatory use requirements.
How does FDA use PBPK models in drug approval decisions?
FDA accepts PBPK modelling as a regulatory tool under the 2018 PBPK Guidance for Industry ↗. Accepted uses: (1) DDI predictions when clinical studies are impractical; (2) paediatric dose selection under PREA ↗; (3) dose labelling for renal and hepatic impairment; (4) food effect and formulation impact prediction. The EMA PBPK reporting guideline ↗ sets the parallel European standard.
What software platforms are commonly used for PBPK?
Widely used PBPK platforms: Simcyp (Certara) ↗ — the most common in FDA/EMA submissions; GastroPlus (Simulations Plus) ↗ — strong in oral absorption prediction; PK-Sim/MoBi (OSP Suite) ↗ — open-source, strong in academic and translational research. All three are referenced in the FDA PBPK guidance ↗. The workshop includes hands-on sessions with multiple platforms.
What is paediatric extrapolation using PBPK?
Paediatric PBPK adjusts adult models by incorporating age-dependent physiological changes: CYP enzyme ontogeny (CYP3A4, CYP2D6 reach adult expression at ~1–3 years; UGT is immature at birth), GFR maturation (near adult values by ~2 years), neonatal protein binding differences, and gestational age-dependent absorption. See our paediatric pharmacology guide. The EMA Paediatric Investigation Plan (PIP) ↗ increasingly incorporates PBPK modelling as evidence. Maharaj et al. CPT 2015 ↗ is a key reference for paediatric PBPK validation.
How are PBPK models verified and validated for regulatory submissions?
FDA expects PBPK regulatory submissions to include: (1) model verification — physiologically plausible parameters, correctly coded; (2) model validation — predicted vs observed PK for ≥2 independent clinical datasets; (3) sensitivity analysis for key uncertain parameters; (4) clear description of model limitations. The FDA 2018 PBPK guidance ↗ and EMA PBPK reporting guideline ↗ provide detailed format requirements. ICH M12 ↗ also addresses PBPK for DDI.